von Tobias Borgers | Apr 11, 2024 | Glaxo
Trelegy Ellipta is approved as a maintenance treatment for COPD and asthma in the US. Image Credit: MAXSHOT.PL / Shutterstock. Singapore’s Health Sciences Authority (HSA) has expanded the label of GlaxoSmithKline (GSK)’s Trelegy Ellipta (fluticasone...
von Tobias Borgers | Apr 11, 2024 | Glaxo
GSK’s respiratory portfolio focuses on therapies for diseases characterised by high eosinophil levels or high T2 inflammation. GSK has successfully concluded the acquisition of Aiolos Bio in a deal that could reach $1.4bn, marking a significant expansion of GSK’s...
von Tobias Borgers | Feb 23, 2024 | Glaxo
GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. As previously...
von Tobias Borgers | Feb 2, 2024 | Glaxo
When Matt Hill, PhD, was in graduate school, the human genome sequence was more or less finished and companies like 454 and Solexa were starting to make waves in next-gen sequencing (NGS). But Hill became more enamored with synthetic biology—engineering the genetic...
von Tobias Borgers | Feb 2, 2024 | Glaxo
Omjjara is the first medicine in the EU specifically indicated for treating splenomegaly (enlarged spleen) or symptoms in adult myelofibrosis patients with moderate to severe anaemia Authorisation may address high unmet need, with nearly all myelofibrosis patients...
von Tobias Borgers | Jan 10, 2024 | Glaxo
Acquisition expands GSK’s respiratory pipeline adding AIO-001, a phase II-ready, long-acting antibody targeting the clinically validated TSLP pathway AIO-001 could redefine the standard-of-care with dosing every six months AIO-001 has potential to expand GSK’s...
